Research Paper Volume 16, Issue 11 pp 9569—9583
Attenuating bone loss in osteoporosis: the potential of corylin (CL) as a therapeutic agent
Figure 8. Inhibition of osteoclast formation in vivo by CL administration. (A) The TRAP staining image from bone samples. (B, C) The histomorphometric quantifying (N.Oc/BS and OcS/BS) of TRAP-positive osteoclasts. ***P < 0.001; ****P < 0.0001.